Med spa UGC: the brief and script for medical spas and aesthetic clinics

Med spa UGC is phone-first video filmed by a real person that your practice commissions, pays for, owns and runs as its own advertising. The defining feature is ownership rather than production value: you brief it, you take delivery of the files from the creator you hired, and the usage terms you agreed with them let you put media spend behind it. That is different from hoping a happy patient tags you.

In aesthetics the category covers more than testimonials. A provider explaining what a treatment actually does, a walkthrough of a clean and calm treatment room, a consultation played out end to end, and an honest recovery diary all belong here. So does content aimed at the business side of the industry, because a practice owner describing the software or devices they use every day is UGC for a B2B buyer and converts on the same mechanics.

What it is not is influencer marketing. You are not renting an aesthetic influencer's audience or paying for a post on their grid. You are writing the brief, taking it to a creator you hire and pay directly, and running the finished video from your own ad account with usage rights you agree with that creator in advance.

Yes, but only with a standalone written HIPAA authorization signed before you publish, and that authorization is not the same document as your intake or treatment consent. A patient testimonial, a before-and-after photo, or any clip that identifies someone and reveals they were treated is protected health information, and using it to promote the practice is marketing under HIPAA.

The authorization has to satisfy 45 CFR 164.508, which sets out core elements that all have to be present. Missing one invalidates the form. In practice that means describing the specific information being used, naming who may disclose it and who may receive it, stating the purpose, setting an expiration, carrying the patient's signature and date, explaining the right to revoke and how, and stating plainly that treatment is not conditioned on signing.

Two details catch practices out repeatedly. The first is bundling: an authorization buried inside the intake packet the patient signed on their first visit does not cover a video you film eighteen months later. It has to stand alone. The second is revocation. A patient can withdraw authorization, and if they do, the ad has to come down, which is a real operational reason to keep a record of which creative maps to which signed form. None of this is legal advice, and state law can be stricter than HIPAA, so run your template past your own counsel.

This is the question that decides how a med spa program is built, and the honest answer runs against how UGC is normally sold. In most categories you hire a creator who is not your customer, send them the product, and they film. In aesthetics that shortcut collapses, because a creator who actually receives a treatment becomes your patient, and a creator who has not received it cannot honestly present themselves as someone who did.

That second half is the part practices underestimate. The FTC Consumer Reviews and Testimonials Rule, effective 21 October 2024, prohibits testimonials by people who do not exist or who never had the experience they describe, and carries civil penalties of up to $53,088 per violation. A paid creator reading a script that implies they were treated at your clinic when they were not is the textbook case. So is an AI-generated presenter.

So there are really only two compliant routes for treatment-experience content, and both are workable. Either the creator genuinely comes in and is treated, in which case they are a patient and you need the HIPAA authorization alongside a clear paid-partnership disclosure, or the content avoids claiming personal treatment experience altogether and does something else useful: provider-led education, a facility tour, a consultation walkthrough, or an honest first-visit-nerves piece that never asserts a result.

Read down that table and the strategy becomes obvious. Build the bulk of the program from formats in rows three, four and five, and treat genuine patient stories as the smaller, highest-trust layer you invest real administrative care in. That is the opposite of how most practices start, which is by asking their happiest patient for a phone video and posting it the same afternoon.

Aesthetics audiences are geographically capped, which means creative fatigues fast. A single metro will see the same ad many times in a week, so the practices that get leverage brief several angles at once and rotate them rather than producing one hero spot they then cannot afford to replace.

Before-and-after imagery deserves its own caution. Several state medical boards impose specific requirements on it, commonly that the images be of actual patients of the practice, unretouched, taken under comparable conditions, and accompanied by a statement that results vary. A few restrict it further. Because these rules are set state by state rather than federally, the only safe approach is to confirm your own board's position before you brief the format, not after the creative comes back.

For the lower-consent formats the production pattern is the same one that works in beauty and skincare: order a batch of hooks against one concept, run them as paid social creative, and keep the winners in rotation while you brief the next batch.

Carefully, and most practices should assume the answer is no by default. Botulinum toxin products are prescription drugs, so promoting them by brand name pulls the ad into FDA prescription drug promotion rules, and the major ad platforms layer their own restrictions on top. Google in particular restricts advertising prescription treatments by brand name in most formats absent certification, which is why so many practices write about neurotoxin, wrinkle relaxers or injectable treatments instead.

The sharper trap is off-label promotion, and here most of the marketing advice circulating online is out of date. BOTOX Cosmetic currently carries four FDA-approved aesthetic indications, not the three that most med spa marketing articles still list: moderate to severe glabellar lines, lateral canthal lines, forehead lines, and platysma bands, the last of which was approved in October 2024. Masseter muscle prominence, the jawline slimming use that is enormously popular in aesthetics content, is not approved. Allergan Aesthetics announced on 4 August 2026 that the FDA had accepted a supplemental application for that indication for review, and acceptance for review is not approval.

That distinction matters directly to how you brief a creator, because it is a treatment that is administered legally every day but cannot be promoted. A practice may perform an off-label treatment where clinically appropriate. Advertising it is a different act governed by different rules.

Which brings the whole page back to one point. The risky sentence in a med spa video is almost never in the script your marketing team approved. It is the line a creator improvises on camera, naming a brand or claiming a result nobody cleared. You cannot filter that out reliably at the review stage, because by then it is the best take. The control has to sit in the brief: name the approved language, name the words that are off limits, and say plainly what the creator may and may not claim about their own outcome.